Tempest Therapeutics (TPST) Retained Earnings (2011 - 2026)

Tempest Therapeutics has reported Retained Earnings for 15 years, with the latest figure at -$233.4 million in Q4 2025.

• Quarterly Retained Earnings fell 203.16% year-over-year to -$233.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$233.4 million (down 203.16% YoY) and the FY2025 annual result came in at -$233.4 million, down 203.16% from the prior year.
• Retained Earnings declined to -$233.4 million in Q4 2025 per TPST's latest filing, from -$229.3 million in the prior quarter.
• Over five years, Retained Earnings peaked at $235.6 million in Q2 2025 and troughed at -$233.4 million in Q4 2025.
• A 5-year average of -$27.3 million and a median of -$104.3 million in 2021 frame the typical range for Retained Earnings.
• The sharpest annual moves came in 2021 and 2025: Retained Earnings surged 4489.59% in 2021, then plunged 203.16% in 2025.
• Over 5 years, Retained Earnings stood at $136.2 million in 2021, then slumped by 199.71% to -$135.8 million in 2022, then decreased by 21.72% to -$165.3 million in 2023, then jumped by 236.89% to $226.2 million in 2024, then slumped by 203.16% to -$233.4 million in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered -$233.4 million, -$229.3 million, and $235.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.